Sharemaestro company-news research for Biogen Inc (BIIB), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Measured evidence
Company news sentiment
BIIB news sentiment
Biogen Inc
Company headlines compared by relevance, subject, source independence, tone and the market's completed price response.
Weighted tone54Neutral is 50
Balanced news tone
64/100 evidence confidence
100% direct company focus
4 current stories across 2 publishers
Current company news
Balanced read
Balanced news tone is drawn from 4 fresh independent stories, including 4 company-specific items across 2 publishers.
Latest source headline NovelMed Advances NM5072 for Multiple Ocular Disorders finance.yahoo.com · 11 Aug 2026 19:27What supports the read
4 current stories are mapped specifically to BIIB.
Cross-story agreement is 87/100, indicating a comparatively coherent tape.
What tempers the read
Only 2 publishers currently contribute to the measured read.
54/100
Weighted toneBalanced news tone
64/100
Evidence confidencesolid confidence
100%/100
Company focus4 direct stories
87/100
Evidence agreement13/100 dispersion
News history
Tone and story flow over 21 days
24 Jul03 Aug13 Aug
Weighted toneStory volumeNeutral 50
Evidence confidence
What supports the score
Confidence rises through sample depth, independent publishers, direct company relevance, freshness and agreement. A high or low tone score is not itself evidence of reliability.
Sample depth43
3.45 effective storiesSource breadth40
2 independent publishersDirect relevance100
company-specific evidence shareFreshness65
recency-weighted evidenceAgreement87
cross-story consistencySource independence23
lower publisher concentrationPrice context
Sentiment against the 26-week price path
News tone and price action are not far from neutral.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
News subjects
What is shaping the score
Regulatory and legal691 stories · 25%
Earnings331 stories · 25%
Deals and strategy591 stories · 25%
Analyst action521 stories · 25%
Source mix
Where the evidence comes from
finance.yahoo.com583 stories · 75%
www.marketscreener.com521 stories · 25%
Recurring subjects
Subjects appearing most often
Fda Approval2Biotech2Rare Diseases1Quarterly Results1Pharmaceuticals1Neurological1Earnings1Clinical Trials1
Earlier readings
How the score has changed
ConstructiveBalanced or withheldCautious
Source headlines
The news behind the score
Every row shows the public evidence used to understand the read. Direct company stories carry more weight than industry or sector context; duplicate coverage is consolidated before scoring.
#159Tone
finance.yahoo.comDirect company coverage
NovelMed Advances NM5072 for Multiple Ocular Disorders
NovelMed Therapeutics Inc Key Highlights Multi-indication precedent: Biogen's approximately $5.6 billion acquisition of Apellis added EMPAVELI for PNH and SYFOVRE for GA, both of which contain pegcetacoplan. Primate proof of concept: A single intravitreal dose of NM5072 reduced CNV, hemorrhage, and retinal fibrosis in a rhesus monkey model. Phase I clinical experience: NM5072 completed a Phase I study in 48 healthy volunteers and received FDA Orphan Drug Designation for PNH. Potential extended durability: Rabbit PK/PD data estimated an ocular half-life of seven days. Translational modeling pro
- Published
- 11 Aug 2026 19:27
- Catalyst
- Deals and strategy
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#269Tone
finance.yahoo.comDirect company coverage
The Galien Foundation Announces 2026 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Product," and "Best Product for Rare/Orphan Diseases"
A Milestone 20th Anniversary Edition Recognizing Excellence in Medical Science and Patient Care NEW YORK, Aug. 11, 2026 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the nominees for the 2026 Prix Galien USA Awards in the "Best Biotechnology Product," "Best Pharmaceutical Product," and "Best Product for Rare/Orphan Diseases" categories. Winners will be honored at the Prix Galien USA Awards Ceremony on October 29, 2026, at the American Museum of Natural History in New York City.logo "We are proud to recog
BiotechFda ApprovalPharmaceuticalsRare Diseases
- Published
- 11 Aug 2026 13:00
- Catalyst
- Regulatory and legal
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#352Tone
www.marketscreener.comDirect company coverage
HSBC Adjusts Price Target on Biogen to $165 From $157, Keeps Reduce Rating
- Published
- 10 Aug 2026 12:57
- Catalyst
- Analyst action
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#433Tone
finance.yahoo.comDirect company coverage
DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum
Denali Therapeutics DNLI reported a second-quarter 2026 loss of 68 cents per share, narrower than the Zacks Consensus Estimate of a loss of 73 cents. The company incurred a loss of 72 cents in the year-ago quarter. In late March, Denali secured a major regulatory win with the FDA approval of its lead pipeline candidate tividenofusp alfa-eknm, under the brand name Avlayah, for the treatment of Hunter Syndrome (MPS II). The FDA granted accelerated approval to Avlayah, marking the first new treatment option in nearly 20 years for patients with Hunter syndrome, a rare lysosomal storage disorder. I
BiotechClinical TrialsEarningsFda ApprovalNeurologicalQuarterly Results
- Published
- 07 Aug 2026 18:31
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
Earlier company news
BIIB news archive
Stored newest first for historical research. These older headlines are retained for reference and do not contribute to the current sentiment gauge above.
Aug
08
2026
Motley FoolArchivedPositive tone
Biogen (BIIB) Q2 2026 Earnings Call Transcript
- Published
- 8 Aug 2026 01:02
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
05
2026
Stock TitanArchivedNeutral tone
Lloyd Minor (BIIB) files Form 144 for 593-share NASDAQ stock sale
- Published
- 5 Aug 2026 00:57
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
04
2026
Investing.com CanadaArchivedNeutral tone
Form 144 BIOGEN INC. For: 3 August By Investing.com
- Published
- 4 Aug 2026 00:10
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
02
2026
MarketWatchArchivedPositive tone
Biogen Inc. stock underperforms Friday when compared to competitors
- Published
- 2 Aug 2026 11:58
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
31
2026
Simply Wall StArchivedPositive tone
Why Biogen (BIIB) Is Up 5.8% After Q2 Revenue Beat And Raised 2026 Guidance - And What's Next
- Published
- 31 Jul 2026 06:33
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
30
2026
MT NewswiresArchivedPositive tone
BMO Capital Adjusts Price Target on Biogen to $208 From $196, Maintains Market Perform Rating
- Published
- 30 Jul 2026 17:06
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
29
2026
marketscreener.comArchivedPositive tone
Earnings Flash (BIIB) Biogen Posts Q2 Total Revenue $2.74B, vs. FactSet Est of $2.46B
- Published
- 29 Jul 2026 13:07
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
29
2026
TradingViewArchivedNeutral tone
Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates?
- Published
- 29 Jul 2026 08:44
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
28
2026
The Globe and MailArchivedNeutral tone
Biogen (BIIB) Reports Q2: Everything You Need To Know Ahead Of Earnings
- Published
- 28 Jul 2026 07:44
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
25
2026
TradingViewArchivedNeutral tone
Biogen Q2 Earnings: Can New Drugs Counter Falling MS Sales?
- Published
- 25 Jul 2026 08:13
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
23
2026
Simply Wall StreetArchivedNeutral tone
At-Home LEQEMBI Autoinjector And New Tau Data Might Change The Case For Investing In Biogen (BIIB)
- Published
- 23 Jul 2026 21:13
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
22
2026
ZacksArchivedNeutral tone
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for
- Published
- 22 Jul 2026 19:07
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
20
2026
MT NewswiresArchivedNeutral tone
Goldman Sachs Adjusts Price Target on Biogen to $271 From $250, Maintains Buy Rating
- Published
- 20 Jul 2026 14:13
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
17
2026
MarketWatchArchivedNeutral tone
Biogen Inc. stock outperforms competitors on strong trading day
- Published
- 17 Jul 2026 18:31
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
10
2026
MoomooArchivedNeutral tone
Biogen Slides as Newly Disclosed Charges Pressure Near-Term Earnings
- Published
- 10 Jul 2026 06:36
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
09
2026
Investing.comArchivedNeutral tone
Maria Elvira Salazar Makes Significant Trades in Biogen, Brookfield Renewable, and Salesforce
- Published
- 9 Jul 2026 12:10
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
08
2026
MarketWatchArchivedNeutral tone
Biogen Inc. stock underperforms Tuesday when compared to competitors
- Published
- 8 Jul 2026 04:21
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
07
2026
marketscreener.comArchivedNeutral tone
Jefferies Adjusts Price Target on Biogen to $255 From $210
- Published
- 7 Jul 2026 11:56
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
06
2026
Market sourceArchivedNeutral tone
Here is Why Biogen (BIIB) is One of the Most Undervalued NASDAQ Stocks to Buy Right Now
- Published
- 6 Jul 2026 09:46
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
05
2026
Motley FoolArchivedNeutral tone
Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.
- Published
- 5 Jul 2026 02:09
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
03
2026
The Globe and MailArchivedNeutral tone
H.C. Wainwright Remains a Buy on Biogen (BIIB)
- Published
- 3 Jul 2026 19:09
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
03
2026
TradingViewArchivedNeutral tone
BIIB Stock Ends 3% Higher — Why This Strategist Picks Biogen Over Other Biotech Peers
- Published
- 3 Jul 2026 13:27
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
30
2026
MSNArchivedPositive tone
Are Wall Street analysts bullish on Biogen stock?
- Published
- 30 Jun 2026 21:46
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
29
2026
BenzingaArchivedPositive tone
Biogen: Key Takeaways From Needham’s Meeting With Top Management
- Published
- 29 Jun 2026 18:34
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
29
2026
Simply Wall StreetArchivedPositive tone
Biogen (BIIB) Is Up 9.9% After US$1 Billion RayThera Deal And Salanersen Win - Has The Bull Case Changed?
- Published
- 29 Jun 2026 05:58
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
28
2026
TradingViewArchivedNeutral tone
Enterprise value to revenue forward of Biogen Inc. – MUN:IDP
- Published
- 28 Jun 2026 14:19
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
27
2026
GuruFocusArchivedPositive tone
Biogen Inc (BIIB) Shares Surge 7.0% -- What GF Score of 74 Tells Investors
- Published
- 27 Jun 2026 06:04
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
26
2026
TradingViewArchivedNeutral tone
Enterprise value to EBIT forward of Biogen Inc. – NASDAQ:BIIB
- Published
- 26 Jun 2026 13:03
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
26
2026
MarketWatchArchivedNeutral tone
Biogen Inc. stock underperforms Thursday when compared to competitors despite daily gains
- Published
- 26 Jun 2026 09:08
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
25
2026
TradingViewArchivedNeutral tone
Price to earnings forward of Biogen Inc. – NASDAQ:BIIB
- Published
- 25 Jun 2026 02:06
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean a balanced tape or that direction has been withheld for insufficient evidence; the status label distinguishes them.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
The page describes completed evidence available at the stated time. It is research context, not a forecast, recommendation, target or execution instruction.